Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial

IMPORTANCE: Safe and effective therapies for untreated, advanced gastric/gastroesophageal junction (G/GEJ) cancer remain an unmet need. OBJECTIVE: To evaluate the antitumor activity of pembrolizumab, pembrolizumab plus chemotherapy, or chemotherapy alone in patients with untreated, advanced G/GEJ ca...

全面介紹

Na minha lista:
書目詳細資料
發表在:JAMA Oncol
Main Authors: Shitara, Kohei, Van Cutsem, Eric, Bang, Yung-Jue, Fuchs, Charles, Wyrwicz, Lucjan, Lee, Keun-Wook, Kudaba, Iveta, Garrido, Marcelo, Chung, Hyun Cheol, Lee, Jeeyun, Castro, Hugo Raul, Mansoor, Wasat, Braghiroli, Maria Ignez, Karaseva, Nina, Caglevic, Christian, Villanueva, Luis, Goekkurt, Eray, Satake, Hironaga, Enzinger, Peter, Alsina, Maria, Benson, Al, Chao, Joseph, Ko, Andrew H., Wainberg, Zev A., Kher, Uma, Shah, Sukrut, Kang, S. Peter, Tabernero, Josep
格式: Artigo
語言:Inglês
出版: American Medical Association 2020
主題:
Original Investigation
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7489405/
https://ncbi.nlm.nih.gov/pubmed/32880601
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2020.3370
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍